Search

Your search keyword '"Eva Settels"' showing total 3 results
Start Over Author "Eva Settels"
3 results on '"Eva Settels"'

1. In vitro efficacy of artemisinin-based treatments against SARS-CoV-2

Author

Yuyong Zhou, Kerry Gilmore, Santseharay Ramirez, Eva Settels, Karen A. Gammeltoft, Long V. Pham, Ulrik Fahnøe, Shan Feng, Anna Offersgaard, Jakob Trimpert, Jens Bukh, Klaus Osterrieder, Judith M. Gottwein, and Peter H. Seeberger

Subjects
Medicine, Science
Abstract

Abstract Effective and affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are needed. We report in vitro efficacy of Artemisia annua extracts as well as artemisinin, artesunate, and artemether against SARS-CoV-2. The latter two are approved active pharmaceutical ingredients of anti-malarial drugs. Concentration–response antiviral treatment assays, based on immunostaining of SARS-CoV-2 spike glycoprotein, revealed that treatment with all studied extracts and compounds inhibited SARS-CoV-2 infection of VeroE6 cells, human hepatoma Huh7.5 cells and human lung cancer A549-hACE2 cells, without obvious influence of the cell type on antiviral efficacy. In treatment assays, artesunate proved most potent (range of 50% effective concentrations (EC50) in different cell types: 7–12 µg/mL), followed by artemether (53–98 µg/mL), A. annua extracts (83–260 µg/mL) and artemisinin (151 to at least 208 µg/mL). The selectivity indices (SI), calculated based on treatment and cell viability assays, were mostly below 10 (range 2 to 54), suggesting a small therapeutic window. Time-of-addition experiments in A549-hACE2 cells revealed that artesunate targeted SARS-CoV-2 at the post-entry level. Peak plasma concentrations of artesunate exceeding EC50 values can be achieved. Clinical studies are required to further evaluate the utility of these compounds as COVID-19 treatment.

Published
2021
Full Text
View/download PDF

2. Human CYP2E1 mediates the formation of glycidamide from acrylamide

Author

Klaus E. Appel, Ulrike Bernauer, Eva Settels, H. Klaffke, Richard Palavinskas, and Ursula Gundert-Remy

Subjects
Adult, Health, Toxicology and Mutagenesis, Metabolite, Hydroxylation, Transfection, Toxicology, Risk Assessment, Gas Chromatography-Mass Spectrometry, Cell Line, Substrate Specificity, chemistry.chemical_compound, Species Specificity, biology.animal, Animals, Humans, Enzyme Inhibitors, Biotransformation, Carcinogen, Acrylamide, biology, Chemistry, Marmoset, Cytochrome P450, Callithrix, Cytochrome P-450 CYP2E1, General Medicine, Middle Aged, Recombinant Proteins, Genetically modified organism, Cytochrome P-450 CYP2E1 Inhibitors, Kinetics, Chlorzoxazone, Biochemistry, Cell culture, Carcinogens, Microsomes, Liver, Microsome, biology.protein, Epoxy Compounds, Female, Ditiocarb
Abstract

Regarding the cancer risk assessment of acrylamide (AA) it is of basic interest to know, as to what amount of the absorbed AA is metabolized to glycidamide (GA) in humans, compared to what has been observed in laboratory animals. GA is suspected of being the ultimate carcinogenic metabolite of AA. From experiments with CYP2E1-deficient mice it can be concluded that AA is metabolized to GA primarily by CYP2E1. We therefore examined whether CYP2E1 is involved in GA formation in non-rodent species with the focus on humans by using human CYP2E1 supersomes™, marmoset and human liver microsomes and in addition, genetically engineered V79 cells expressing human CYP2E1 (V79h2E1 cells). Special emphasis was placed on the analytical detection of GA, which was performed by gas chromatography/mass spectrometry. The results show that AA is metabolized to GA in human CYP2E1 supersomes™, in marmoset and human liver microsomes as well as in V79h2E1 cells. The activity of GA formation is highest in supersomes™; in human liver it is somewhat higher than in marmoset liver. A monoclonal CYP2E1 human selective antibody (MAB-2E1) and diethyldithiocarbamate (DDC) were used as specific inhibitors of CYP2E1. The generation of GA could be inhibited by MAB-2E1 to about 80% in V79h2E1 cells and to about 90% in human and marmoset liver microsomes. Also DDC led to an inhibition of about 95%. In conclusion, AA is metabolized to GA by human CYP2E1. Overall, the present work describes (1) the application and refinement of a sensitive methodology in order to determine low amounts of GA, (2) the applicability of genetically modified V79 cell lines in order to investigate specific questions concerning metabolism and (3) the involvement, for the first time, of human CYP2E1 in the formation of GA from AA. Further studies will compare the activities of GA formation in genetically engineered V79 cells expressing CYP2E1 from different species.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results